drugset / Trial / NCT05189093
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a multi-center, open, single-arm phase I/II clinical study to evaluate the recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Chinese patients with relapsed/refractory lymphoma .
Timeline
- Start
- 2021-12-31
- Primary completion
- 2025-06-25
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HX009 | Protein / enzyme biologic | 10 mg/kg | — |
| Subject | HX009 | Protein / enzyme biologic | 15 mg/kg | — |